SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer
Condition(s):Metastatic Renal Cell CarcinomaLast Updated:March 23, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):Metastatic Renal Cell CarcinomaLast Updated:March 23, 2023Recruiting
Condition(s):Squamous Cell Carcinoma of the Head and NeckLast Updated:January 25, 2024Active, not recruiting
Condition(s):MelanomaLast Updated:April 27, 2017Completed
Condition(s):Hodgkin Lymphoma; Relapsed Hodgkin’s Disease, Adult; Refractory Hodgkin LymphomaLast Updated:March 20, 2024Active, not recruiting
Condition(s):MelanomaLast Updated:February 28, 2024Recruiting
Condition(s):Melanoma; Non Small Cell Lung CancerLast Updated:February 8, 2022Completed
Condition(s):Prostate CancerLast Updated:September 25, 2023Completed
Condition(s):Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell LungLast Updated:January 17, 2024Completed
Condition(s):MelanomaLast Updated:February 1, 2016Unknown status
Condition(s):Metastatic MelanomaLast Updated:November 8, 2022Terminated
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.